Katarina Uttervall

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2024;16(5):1024

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Partanen A; Waage A; Peceliunas V; Schjesvold F; Anttila P; Säily M; Uttervall K; Putkonen M; Carlson K; Haukas E; Sankelo M; Szatkowski D; Hansson M; Marttila A; Svensson R; Axelsson P; Lauri B; Mikkola M; Karlsson C; Abelsson J; Ahlstrand E; Sikiö A; Klimkowska M; Matuzeviciene R; Fenstad MH; Ilveskero S; Pelliniemi T-T; Nahi H; Silvennoinen R
Article: CANCER MEDICINE. 2023;12(22):20736-20744

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Nahi H; Afram G; Uttervall K; Lockmer S; Tätting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933

Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Månsson R; Wagner AK; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554

Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.

Afram G; Susek KH; Uttervall K; Wersäll JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(6):588-596

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

Gran C; Uttervall K; Borg Bruchfeld J; Wallblom A; Alici E; Gahrton G; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254

Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.

Uttervall K; Borg Bruchfeld J; Gran C; Wålinder G; Månsson R; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;99(3):216-222

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H; Genell A; Wålinder G; Uttervall K; Juliusson G; Karin F; Hansson M; Svensson R; Linder O; Carlson K; Björkstrand B; Kristinsson SY; Mellqvist UH; Blimark C; Turesson I
Article: PLOS ONE. 2015;10(9):e0138248

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.

Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegård M; Forsberg K; Gruber A; Haglöf Kviele H; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Näsman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.

Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: PLOS ONE. 2014;9(7):e101819

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.

Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.

Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: MEDICAL ONCOLOGY. 2012;29(3):2191-2199

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery.

Ungerstedt JS; Watz E; Uttervall K; Johansson B-M; Wahlin BE; Näsman P; Ljungman P; Gruber A; Axdorph Nygell U; Nahi H

Alla övriga publikationer

Meeting abstract: BLOOD. 2023;142:1960

A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk

Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225

Response to Caravita di Toritto and Rago.

Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Meeting abstract: BLOOD. 2022;140:12605-12606

Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

Uttervall K; Nahi H; Kashif M; Lemonakis K; Rosengren S; Brolin J; Lund J; Hansson M
Meeting abstract: BLOOD. 2021;138:897

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Callander NS; Ribrag V; Richardson PG; Nooka AK; Song K; Uttervall K; Minnema MC; Weisel K; Quach H; Min C-K; Ballas MS; Li XF; Ratia N; Kaisermann M; Holkova B; Tudel S
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.

Lockmer S; Uttervall K; Kashif M; Svärd C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Meeting abstract: BLOOD. 2012;120(21):5033

Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients

Uttervall K; Andreasson J; Liwing J; Nasman P; Aschan J; Nahi H
Meeting abstract: BLOOD. 2012;120(21):2970

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population

Nahi H; Liwing J; Aldrin A; Andreasson J; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Johansson P; Kviele H; Lauri B; Mellqvist U-H; Nasman P; Swedin A; Svensson M; Uttervall K; Aschan J

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2015
Läkarexamen, Karolinska Institutet, 2009

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI